Vir Biotechnology is a clinical-stage immunology company that engineers antibodies into medicines targeting serious infectious diseases and cancer. Its programs span chronic hepatitis delta, hepatitis B, oncology, and prior work on COVID-19 and Ebola, built on a next-generation antibody platform and the licensed PRO-XTEN protease-releasable… - View it on GitHub